Safety of Recombinant Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
The study aims to show that the candidate malaria vaccine GMZ2 is as safe as the already publicly used vaccine against rabies. 40 adult male Gabonese volunteers will be enrolled and randomly allocated to receive either malaria vaccine or rabies vaccine without the investigator or the participants knowing what they received. They will receive 3 doses each at one month intervals, and will be followed up for one year to evaluate safety parameters. This is the first time this product will be tested in Africa
Epistemonikos ID: ae374bc770d7a4c206fc474a1853ff10d791307d
First added on: May 04, 2024